Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter ...

9 hours ago · Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 …

CouponFollow Extension

60%
OFF

Diabetes And Obesity Drugs Fuel Eli Lilly Profit In The Final Quarter ...

2 weeks from now

9 hours ago · Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound …

go.com

90%
OFF

Eli Lilly's Quarterly Results Top Estimates As Obesity, Diabetes Drugs ...

2 weeks from now

Feb 6, 2024 · About 90% of U.S. Type 2 diabetes patients with commercial insurance or Medicare Part D prescription-drug plans now have access to Lilly's diabetes drug Mounjaro, the …

morningstar.com

28%
OFF

Weight Loss, Diabetes Drugs Propel Eli Lilly To Largely Better-than ...

2 weeks from now

Feb 6, 2024 · Overall, Lilly booked a $2.19 billion profit in the final quarter of 2023. Earnings adjusted for one-time items came to $2.49 per share. Revenue grew 28% to $9.35 billion.

yahoo.com

$175
OFF

Eli Lilly Soars On Diabetes And Obesity Drug Boom, Projects

2 weeks from now

Feb 6, 2024 · In the fourth quarter, Zepbound, Lilly's weight-loss drug offering, recorded $175.8 million in global sales. The company’s overall fourth-quarter revenues stood at $9.35 billion, …

benzinga.com

$2.21
OFF

Eli Lilly Expects Obesity And Diabetes Drugs To Deliver Hefty Profit …

2 weeks from now

Feb 6, 2024 · Lilly reported sales of Mounjaro for the quarter rose to $2.21bn from $279.2m last year, easily outpacing expectations of $1.8bn, according to BMO Capital Markets.

businesslive.co.za

$580
OFF

Eli Lilly Earnings: Strong Diabetes And Obesity Sales Continue

2 weeks from now

Aug 8, 2024 · We are increasing our fair value estimate for Eli Lilly LLY to $580 per share from $540 following better-than-expected second-quarter results, largely driven by Mounjaro (its …

morningstar.com

72%
OFF

Sales Of Obesity Drugs Push Novo Nordisk, Eli Lilly To Top In Q2

2 weeks from now

Aug 15, 2023 · Mounjaro, which was approved for diabetes midway through the second quarter of 2022, bolstered Lilly with $980 million in sales in the quarter. The drug jumped 72% from the …

fiercepharma.com

FAQs about Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter ... Coupon?

How did Eli Lilly & Co stock perform in premarket trading?

Eli Lilly and Co. shares slipped 1% to $831.64 Thursday in premarket trading. The stock had already climbed 9% so far this year, as of Wednesday. Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. ...

How did Lilly perform in 2024?

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 billion. Revenue from the breast cancer treatment Verzenio also helped, climbing 36% to $1.55 billion. ...

How did Lilly's earnings compare to Wall Street's expectations?

Overall, Lilly’s quarterly profit swelled to $4.41 billion. Revenue advanced 45% to $13.53 billion, in line with expectations. Per-share earnings adjusted for one-time items totaled $5.32, easily topping the $5.01 that Wall Street was looking for, according to a poll of industry analysts by FactSet. ...